|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LILRB3 |
Gene summary for LILRB3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LILRB3 | Gene ID | 11025 |
| Gene name | leukocyte immunoglobulin like receptor B3 | |
| Gene Alias | CD85A | |
| Cytomap | 19q13.42 | |
| Gene Type | protein-coding | GO ID | GO:0002250 | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 11025 | LILRB3 | HCC1 | Human | Liver | HCC | 2.24e-04 | 7.37e-01 | 0.5336 |
| 11025 | LILRB3 | HCC2 | Human | Liver | HCC | 6.60e-16 | 1.44e+00 | 0.5341 |
| 11025 | LILRB3 | HCC5 | Human | Liver | HCC | 2.97e-20 | 1.42e+00 | 0.4932 |
| Page: 1 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003009922 | Liver | HCC | myeloid cell differentiation | 200/7958 | 381/18723 | 4.64e-05 | 4.49e-04 | 200 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| ANGPTL2 | LILRB3 | ANGPTL2_PIRB | ANGPTL | Breast | DCIS |
| ANGPTL1 | LILRB3 | ANGPTL1_PIRB | ANGPTL | Breast | DCIS |
| ANGPTL2 | LILRB3 | ANGPTL2_PIRB | ANGPTL | Breast | IDC |
| ANGPTL2 | LILRB3 | ANGPTL2_PIRB | ANGPTL | Cervix | CC |
| ANGPTL2 | LILRB3 | ANGPTL2_PIRB | ANGPTL | Cervix | Precancer |
| ANGPTL1 | LILRB3 | ANGPTL1_PIRB | ANGPTL | Endometrium | Healthy |
| ANGPTL2 | LILRB3 | ANGPTL2_PIRB | ANGPTL | HNSCC | ADJ |
| ANGPTL1 | LILRB3 | ANGPTL1_PIRB | ANGPTL | HNSCC | ADJ |
| ANGPTL2 | LILRB3 | ANGPTL2_PIRB | ANGPTL | HNSCC | OSCC |
| ANGPTL1 | LILRB3 | ANGPTL1_PIRB | ANGPTL | HNSCC | OSCC |
| ANGPTL2 | LILRB3 | ANGPTL2_PIRB | ANGPTL | HNSCC | Precancer |
| ANGPTL1 | LILRB3 | ANGPTL1_PIRB | ANGPTL | HNSCC | Precancer |
| ANGPTL1 | LILRB3 | ANGPTL1_PIRB | ANGPTL | Liver | Precancer |
| ANGPTL1 | LILRB3 | ANGPTL1_PIRB | ANGPTL | Lung | AAH |
| ANGPTL1 | LILRB3 | ANGPTL1_PIRB | ANGPTL | Lung | ADJ |
| ANGPTL1 | LILRB3 | ANGPTL1_PIRB | ANGPTL | Lung | AIS |
| ANGPTL2 | LILRB3 | ANGPTL2_PIRB | ANGPTL | Lung | IAC |
| ANGPTL1 | LILRB3 | ANGPTL1_PIRB | ANGPTL | Lung | IAC |
| ANGPTL1 | LILRB3 | ANGPTL1_PIRB | ANGPTL | Lung | MIAC |
| ANGPTL1 | LILRB3 | ANGPTL1_PIRB | ANGPTL | Lung | Precancer |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| LILRB3 | SNV | Missense_Mutation | rs199861387 | c.931N>A | p.Asp311Asn | p.D311N | O75022 | protein_coding | deleterious(0) | benign(0.255) | TCGA-A8-A08T-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| LILRB3 | SNV | Missense_Mutation | novel | c.1609N>A | p.Glu537Lys | p.E537K | O75022 | protein_coding | tolerated(0.06) | benign(0.23) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
| LILRB3 | SNV | Missense_Mutation | novel | c.1358N>G | p.Val453Gly | p.V453G | O75022 | protein_coding | deleterious(0.03) | possibly_damaging(0.802) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| LILRB3 | SNV | Missense_Mutation | novel | c.559A>C | p.Thr187Pro | p.T187P | O75022 | protein_coding | deleterious(0.04) | benign(0.212) | TCGA-D8-A1Y1-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | tamoxiphen | PD |
| LILRB3 | SNV | Missense_Mutation | rs199861387 | c.931N>A | p.Asp311Asn | p.D311N | O75022 | protein_coding | deleterious(0) | benign(0.255) | TCGA-DS-A5RQ-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | cisplatin | CR |
| LILRB3 | SNV | Missense_Mutation | novel | c.1858N>G | p.Pro620Ala | p.P620A | O75022 | protein_coding | deleterious(0.02) | benign(0.233) | TCGA-EK-A2RJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| LILRB3 | SNV | Missense_Mutation | novel | c.638N>A | p.Pro213His | p.P213H | O75022 | protein_coding | deleterious(0) | probably_damaging(0.973) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| LILRB3 | SNV | Missense_Mutation | novel | c.467N>C | p.Met156Thr | p.M156T | O75022 | protein_coding | tolerated(1) | benign(0.02) | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| LILRB3 | SNV | Missense_Mutation | novel | c.1079G>A | p.Gly360Glu | p.G360E | O75022 | protein_coding | deleterious(0.02) | probably_damaging(0.991) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| LILRB3 | SNV | Missense_Mutation | rs369888262 | c.1100N>A | p.Arg367His | p.R367H | O75022 | protein_coding | tolerated(0.3) | benign(0.087) | TCGA-AA-A01V-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |